Sarepta stock rating cut by Morgan Stanley on patient safety concerns

Morgan Stanley downgraded Sarepta Therapeutics to Equalweight with a price target of $40 from $113, citing safety concerns after a second patient death linked to its Elevidys treatment. The downgrade follows the suspension of shipments for non-ambulatory patients and multiple analyst downgrades from firms like H.C. Wainwright and BMO Capital due to acute liver failure risks, while UBS reiterated a buy rating and Scotiabank upgraded the stock, reflecting mixed analyst sentiment amid regulatory uncertainties.

Analysis

Sarepta Therapeutics (NASDAQ:SRPT) faces significant headwinds following Morgan Stanley's downgrade from Overweight to Equalweight and a drastic price target reduction to $40.00 from $113.00, primarily driven by severe safety concerns after a second patient death associated with its Elevidys treatment for Duchenne muscular dystrophy. This event has led to the suspension of Elevidys shipments for non-ambulatory patients and contributed to the stock's precipitous decline of over 70% year-to-date, with it currently trading at $20.74. The negative outlook is underscored by InvestingPro data indicating 11 recent downward earnings revisions from analysts. Morgan Stanley highlights that while the fatalities appear specific to non-ambulatory patients, the near-term uncertainty is substantial, although an enhanced immunosuppressive regimen currently in development could potentially mitigate these risks. The broader market sentiment, reflected by a strongly negative sentiment score of -0.75 for the news and -0.8 for SRPT specifically, is echoed in multiple downgrades from other firms: H.C. Wainwright to Sell with a $10.00 price target, BMO Capital to Market Perform ($70.00), and Piper Sandler to Neutral ($36.00), all citing acute liver failure risks. However, analyst opinion is not uniformly negative, with UBS maintaining a Buy rating ($85.00) and Scotiabank upgrading to Sector Outperform ($80.00), suggesting a perceived favorable risk-reward scenario by some despite the evident regulatory and safety uncertainties.

Key Decisions for Investors

• Investors should exercise extreme caution given the severe safety issues surrounding Elevidys, the significant stock depreciation, and the preponderance of analyst downgrades, which collectively signal substantial near-term uncertainty for Sarepta Therapeutics.
• Closely monitor forthcoming data and regulatory feedback on the enhanced immunosuppressive regimen, as its success or failure will be a critical determinant in mitigating safety concerns and potentially altering the company's trajectory.
• Evaluate any adjustments to positions based on further clarity regarding the commercial viability of Elevidys given current restrictions, ongoing regulatory scrutiny, and any emerging consensus among analysts whose price targets currently range widely from $10.00 to $85.00.